Mehdi H Hamadani, MD | Medical College of Wisconsin

Mehdi H. Hamadani, MD

Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital
Cancer Center - Moorland Reserve Health Center

Specialties

Hematology
Medical Oncology

Languages

English, Urdu, Hindi, Punjabi

Cancer Center - Froedtert Hospital

(414) 805-0505

Moorland Reserve Health Center

(262) 798-7200

Education

MD - Doctor of Medicine

Biography

Mehdi Hamadani, MD, is A a professor of medicine at the Medical College of Wisconsin, Division of Hematology & Oncology, specializing in lymphoma, and bone marrow transplantation. Dr. Hamadani serves as the Director of the Adult Blood and Marrow Transplant Program (BMT) at Froedtert Hospital. He graduated from King Edward Medical College (with honors) in Pakistan in 2001, he then completed his internal medicine residency at Oklahoma University Health Sciences Center and a Fellowship in Hematology and Oncology at The Ohio State University. He received the James V. Warren Award for Accomplishments as The Most Outstanding Research Fellow, during his fellowship.

Research Interests

Dr. Hamadani has authored over 200 peer-reviewed publications, and has been invited as a speaker for several national and international meetings. He is the recipient of Conquer Cancer Foundation of ASCO Career Development Award and ASBMT New Investigator Award. Dr. Hamadani has also received several Best Attending Physician, Outstanding Teacher, Press Ganey Top Provider and Best Doctors in America Awards. His clinical research focuses on lymphoid malignancies and hematopoietic cell transplantation. Dr. Hamadani is board certified in Hematology and Medical Oncology.

Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma.

(Munshi PN, Chen Y, Ahn KW, Awan FT, Cashen A, Shouse G, Shadman M, Shaughnessy P, Zurko J, Locke FL, Goodman AM, Bisneto JCV, Sauter C, Kharfan-Dabaja MA, Meyers G, Jaglowski S, Herrera A, Hamadani M.) Transplant Cell Ther. 2022 Aug;28(8):487.e1-487.e7 PMID: 35609865 SCOPUS ID: 2-s2.0-85132887608 05/25/2022
Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma.

(Hamadani M, Chen L, Song Y, Xu MK, Liao L, Caimi PF, Carlo-Stella C.) Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e738-e744 PMID: 35513980 05/07/2022
Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy.

(Alseraihy A, McGrath E, Niederwieser D, Chabannon C, Szer J, Mohty M, Kharfan-Dabaja MA, Orchard K, Schwartz J, Rasheed W, Koh M, Kr??ger N, Kodera Y, Fakih RE, Worel N, Manson L, Rintala T, Tabakhi A, Savani B, Gergis U, Sureda A, Eldridge PW, Yakoub-Agha I, Hamadani M, Weisdorf D, Greinix H, Aljurf M.) Transplant Cell Ther. 2022 Aug;28(8):455-462 PMID: 35413459 04/13/2022
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma.

(Calabretta E, Hamadani M, Zinzani PL, Caimi P, Carlo-Stella C.) Blood. 2022 07 28;140(4):303-308 PMID: 35580172 05/18/2022
Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes.

(Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D'Souza A, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, P??rez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, Horowitz M, Auletta JJ, Shaw BE, Arora M.) Transplant Cell Ther. 2022 07;28(7):409.e1-409.e10 PMID: 35447374 SCOPUS ID: 2-s2.0-85130441260 04/22/2022
Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access.

(Ahmed N, Shahzad M, Shippey E, Bansal R, Mushtaq MU, Mahmoudjafari Z, Faisal MS, Hoffmann M, Abdallah AO, Divine C, Hamadani M, McGuirk J, Shune L.) Transplant Cell Ther. 2022 07;28(7):358-364 PMID: 35429662 04/17/2022
ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy.

(Ahmed N, Kumar A, Kharfan-Dabaja MA, DeFilipp Z, Herrera A, Hashmi S, Dholaria B, Perales MA, Carpenter PA, Hamadani M.) Transplant Cell Ther. 2022 Jun 06 PMID: 35671986 06/08/2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.

(Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, Usmani S, Kumar S.) Transplant Cell Ther. 2022 06;28(6):284-293 PMID: 35306217 SCOPUS ID: 2-s2.0-85128352615 03/21/2022
The Evolution of Our Understanding of Immunoproliferative Small Intestinal Disease (IPSID) over Time.

(AlYamany R, Kharfan-Dabaja MA, Hamadani M, Alshaibani A, Aljurf M.) Curr Oncol. 2022 05 23;29(5):3759-3769 PMID: 35621691 PMCID: PMC9139652 05/28/2022
Reality check: Real-world evidence to support therapeutic development in hematologic malignancies.

(Derman BA, Belli AJ, Battiwalla M, Hamadani M, Kansagra A, Lazarus HM, Wang CK.) Blood Rev. 2022 05;53:100913 PMID: 35272867 03/12/2022
Rap1A, Rap1B, and I?-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.

(Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM.) Yale J Biol Med. 2022 03;95(1):45-56 PMID: 35370486 PMCID: PMC8961707 SCOPUS ID: 2-s2.0-85127524780 04/05/2022
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data.

(Furqan F, Hamadani M.) Ther Adv Hematol. 2022;13:20406207221087511 PMID: 35340719 PMCID: PMC8943462 03/29/2022